[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Enliven Therapeutics insider sale reported. Joseph P. Lyssikatos, Chief Scientific Officer and trustee of a revocable trust holding shares, reported a sale of 1,500 shares of Enliven Therapeutics (ELVN) common stock on 09/23/2025 at $20.03 per share. After the reported transaction, the filing shows 931,688 shares beneficially owned indirectly through The Lyssikatos Revocable Trust dated 12/15/2011. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. The Form 4 was submitted by a power of attorney on 09/25/2025.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating the transaction was prearranged and not a timed reaction to undisclosed information
• Reporting includes clear disclosure of indirect trust ownership, showing transparency about the reporting person's holdings

Negative

• None.

Insights

Securities Analyst

TL;DR: Small scheduled insider sale under a pre-established 10b5-1 plan; likely routine rather than a signal of new information.

The transaction is a sale of 1,500 shares at $20.03 executed under a Rule 10b5-1 plan adopted in November 2024, indicating it was prearranged and likely not based on undisclosed company developments. The post-transaction beneficial ownership remains sizable at 931,688 shares held indirectly via a revocable trust, which suggests ongoing alignment with shareholder interests. Given the sale size relative to total reported holdings, the direct market impact is likely minimal.

Corporate Governance Expert

TL;DR: Compliance appears proper; disclosure includes 10b5-1 plan and trust holdings, meeting filing norms.

The Form 4 discloses the relationship of the reporting person as an officer and trustee, cites the Rule 10b5-1 plan adoption date, and documents indirect ownership via a revocable trust, which aligns with standard governance and SEC reporting practices. The filing was executed by power of attorney and includes the required explanation footnotes. No material departures from typical Section 16 reporting requirements are evident in the reported data.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lyssikatos Joseph P

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/23/2025		S(1)		1,500	D	$20.03	931,688	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

	/s/ Ben Hohl, by power of attorney	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ELVN insider Joseph P. Lyssikatos report on Form 4?

He reported a sale of 1,500 shares of ELVN common stock on 09/23/2025 at $20.03 per share under a Rule 10b5-1 plan.

How many ELVN shares does the reporting person own after the sale?

931,688 shares beneficially owned indirectly through The Lyssikatos Revocable Trust dated 12/15/2011.

Was the sale part of a pre-established trading arrangement?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 11/15/2024.

What is the reporting person’s role at Enliven Therapeutics (ELVN)?

He is listed as Chief Scientific Officer and the filing indicates he serves as trustee of the revocable trust holding the shares.

When was the Form 4 filed and who signed it?

The form shows the transaction date 09/23/2025 and was signed via power of attorney on 09/25/2025 by Ben Hohl.